Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

BioNTech SE

Johnson & Johnson

Pfizer

Coronavirus variants will be the key variable.

How Big of an Impact Will COVID-19 Have on the Stock Market Going Forward?

Vaccination rates will determine what happens next.

How This Warning from Dr. Fauci May Equal Higher Revenue for Moderna

How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?

With Moderna stock at $321.11, investors can buy the August $325 call option that expires Aug. 6 and sell the August $350 call with the same expiration. The “spread” costs about $9 and is worth $16 if the stock is at $350 or higher.

Worried About a Covid Resurgence? Consider This Moderna Trade.

Lexaria Bioscience Corp (NASDAQ: LEXX) has announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. The study demonstrated that DehydraTECH enabled colchicine, one of the products tested by Lexaria with known SARS-CoV-2 antiviral properties, benefited from its proprietary formulation and processing, resulting in increased delivery.

Lexaria Stock Is Trading Higher As DehydraTECH Delivered Colchicine Can Potentially Treat COVID-19, Side Effects From mRNA Shots

Moderna's stock dropped 2% in a volatile session on Tuesday, with the COVID-19 vaccine maker the most heavily traded company on Wall Street ahead of its debut in the S&P 500 on Wednesday.

Moderna dominates Wall St trading ahead of S&P 500 debut

Carrier Global

Duke Energy

Equity Residential

Otis Worldwide

Retail Value Inc

Standard Lithium Ltd

Momentum stocks turn the idea of "buy low, sell high" on its head. These seven stocks are on the rise and don't show signs of stopping.

7 Great Momentum Stocks to Buy Before July Ends

The vaccine sector is in the spotlight again today, with Moderna Inc (NASDAQ:MRNA) at the masthead.

Vaccine Stock Options Traders Are Targeting Right Now

Novavax

Ocugen, Inc.

QuidelOrtho Corp

Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the Move Today appeared first on InvestorPlace.

Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the Move Today

Moderna stock rallied by more than 20% over the last week, significantly outperforming the S&P 500 which was down by about 1%. The recent rally comes as Moderna is set to be included in the S&P 500 index starting from July 21.

Moderna Stock: Next Stop $400?

Moderna, Inc. (NASDAQ: MRNA) shares appear to be going from strength to strength, and the premarket price action Tuesday suggests a positive open for the fifth straight session. What Happened: Cambridge, Massachusetts-based Moderna said Japan's Ministry of Health, Labor and Welfare and its Japanese partner Takeda Pharmaceutical Company Limited (NYSE: TAK) have agreed to purchase an additional 50 million doses of its COVID-19 vaccine and its updated variant booster vaccine candidate, contingent on authorization for the latter.

Moderna Extends Rally With Expanded Japanese COVID-19 Vaccine Supply Deal

It isn't about to get any cheaper anytime soon.

Is Now the Right Time to Buy Moderna Stock?

FuboTV

Pinterest

Even if you love these stocks, it may not be a bad move to cash out right now.

3 Expensive Stocks I'd Sell Before the Next Market Crash

Moderna Inc (NASDAQ: MRNA) has announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) will purchase and distribute an additional 50 million doses of Moderna's COVID-19 vaccine and its variant booster shot, if authorized, to begin delivery in 2022. This new supply agreement is in addition to the prior arrangement for 50 million doses in 2021, resulting in 100 million doses for Japan.

Japan To Buy Additional 50M Doses Of Moderna COVID-19 Vaccine

The stock price of Moderna Inc (NASDAQ: MRNA) increased by 9.48% yesterday, going from a previous close of $286.43 to $313.59. This is why it happened.

MRNA Stock Increased 9.48%: Why It Happened

Takeda Pharmaceutical

Shares of Moderna Inc. rose 1.4% in premarket trading Tuesday, after the biotechnology company said it has partnered with Takeda Pharmaceutical Co. Ltd. and the Ministry of Health, Labour and Welfare of Japan to supply an additional 50 million doses of Moderna's COVID-19 vaccine in 2022.

Moderna partners with Takeda, Japanese government on additional 50 million COVID-19 vaccine doses

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna partners with Takeda and the government of Japan to supply 50 million doses of Moderna's COVID-19 Vaccine & booster vaccine candidate in 2022.

Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna's COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022

AMC Entertainment

GameStop

The investment thesis for these high-flying stocks no longer holds water.

It's Time to Book Profits in These 3 Ultra-Popular Stocks

They could result in a broader market for Pfizer's vaccine.

3 Areas Where Pfizer Is Crushing Moderna

Are Booster Doses of Pfizer's and Moderna's COVID Vaccines on the Way?

Co-Diagnostics

Vaxart

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.

Why Coronavirus Stocks Are Zooming Higher Today

Moderna, known for its success in the COVID-19 vaccine, has entered the big league with its addition to the S&P 500 Index.

Moderna Soars on Inclusion to S&P 500: ETFs in Focus

Chevron

Goldman Sachs

Peloton

The Dow was down more than 750 points Monday morning.

Is This the Long-Awaited Stock Market Crash?

A Japanese health ministry panel has backed Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine for emergency use in children aged between 12 to 17 years, paving the way for final approval by the ministry in the coming days. The panel recommended lowering the current age restriction of 18 and older without conducting an additional clinical trial in the country.

Japan Health Ministry Supports Lowering Minimum Age For Moderna's COVID-19 Vaccine To 12 Years

There's no guarantee that the biotech's share price will continue climbing.

News for Moderna Stock (MRNA)